Evidence map›Paper›PMID 31035311›Full record

ArticleKidney research and clinical practice2019

Physicians' perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey.

Ran-Hui Cha, Su Hyun Kim, Eun Hui Bae, Mina Yu, Beom Soon Choi, Hoon Young Choi, Sun Woo Kang, Jungho Shin, Sang Youb Han, Chul Woo Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney research and clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Renal effects of uric acid: hyperuricemia and hypouricemia.The Korean journal of internal medicine · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ran-Hui ChaDepartment of Internal Medicine, National Medical Center, Seoul, Korea.ORCID http://orcid.org/0000-0003-2783-2600
Su Hyun KimDepartment of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0003-3382-528X
Eun Hui BaeDepartment of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.ORCID http://orcid.org/0000-0003-1727-2822
Mina YuDepartment of Internal Medicine, Seonam Hospital, Seoul, Korea.ORCID http://orcid.org/0000-0003-4977-2741
Beom Soon ChoiDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID http://orcid.org/0000-0002-1412-9951
Hoon Young ChoiDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0002-4245-0339
Sun Woo KangDepartment of Nephrology, Inje University Busan Paik Hospital, Busan, Korea.ORCID http://orcid.org/0000-0002-8498-3176
Jungho ShinDepartment of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0001-9755-3100
Sang Youb HanDepartment of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.ORCID http://orcid.org/0000-0003-3312-0597
Chul Woo YangDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID http://orcid.org/0000-0001-9796-636X
Duk-Hee KangDepartment of Internal Medicine, School of Medicine, Ewha Womans University, Seoul, Korea.ORCID http://orcid.org/0000-0001-8475-8932

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperuricemia is associated with the development and progression of chronic kidney disease (CKD) as well as cardiovascular diseases. However, there is no consistent recommendation regarding the treatment of asymptomatic hyperuricemia (AHU) in CKD patients. Here, we surveyed Korean physicians' perceptions regarding the diagnosis and management of AHU in CKD patients.

methodsQuestionnaires on the management of AHU in CKD patients were emailed to regular members registered with the Korean Society of Nephrology.

resultsA total of 158 members answered the questionnaire. Among the respondents, 49.4%/41.1% were considered hyperuricemic in male CKD patients whereas 36.7%/20.9% were considered hyperuricemic in female CKD patients when defined by serum uric acid level over 7.0/8.0 mg/dL, respectively. A total of 80.4% reported treating AHU in CKD patients. The most important reasons to treat AHU in CKD patients were renal function preservation followed by cerebro-cardiac protection. Majority of respondents (59.5%) thought that uric acid-lowering agents (ULAs) were the most effective method for controlling serum uric acid levels. Approximately 80% chose febuxostat as the preferred medication. A total of 32.3% and 31.0%, respectively, initiated ULA treatment if the serum uric acid level was more than 8.0 or 9.0 mg/dL, respectively. In addition, 39.2% and 30.4% answered that target serum uric acid levels of less than 6.0 or 7.0 mg/dL, respectively, were appropriate. The two major hurdles to prescribing ULAs were concerns of adverse reactions and the existing lack of evidence (i.e., the absence of Korean guidelines).

conclusionMost Korean physicians treat AHU in CKD patients to prevent CKD progression and cerebro-cardiovascular complications.

Indexed as

Asymptomatic hyperuricemiaChronic kidney diseaseSurveyTreatment

Identifiers

PMID31035311
PMCPMC6727886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.